Lineage Cell Therapeutics
LCTX
LCTX
131 hedge funds and large institutions have $176M invested in Lineage Cell Therapeutics in 2026 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 37 increasing their positions, 26 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
4% more capital invested
Capital invested by funds: $170M → $176M (+$6.71M)
0.7% more ownership
Funds ownership: 44.14% → 44.84% (+0.7%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Holders
131
Holding in Top 10
2
Calls
$226K
Puts
$38K
Top Buyers
| 1 | +$7.76M | |
| 2 | +$5.82M | |
| 3 | +$5.37M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$2.87M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2M |
Top Sellers
| 1 | -$634K | |
| 2 | -$472K | |
| 3 | -$454K | |
| 4 |
Two Sigma Investments
New York
|
-$298K |
| 5 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$294K |
